1-11 of 11
Mark Kaminski
Close
Sort by
Journal Articles

Functional Analyses of BTK Mutations in Follicular Lymphoma

Nan Hu, PhD, Fangyang Wang, Denzil Bernard, Shaomeng Wang, Mark Kaminski, Sumana Devata, MD, Tycel J. Phillips, MD, Sami N. Malek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 647.
https://doi.org/10.1182/blood.V130.Suppl_1.647.647
Published: 2017
Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD
Journal: Blood
Blood (2014) 124 (21): 3046.
https://doi.org/10.1182/blood.V124.21.3046.3046
Published: 2014
Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2127.
https://doi.org/10.1182/blood.V124.21.2127.2127
Published: 2014
Journal Articles

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Clinical Trials & Observations
Andrzej J. Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian Nordgren, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, Diane E. Durecki, Kathryn McDonnell, Melissa Mietzel, Daniel Couriel, Mark Kaminski, Ravi Vij
Journal: Blood
Blood (2012) 120 (9): 1801–1809.
https://doi.org/10.1182/blood-2012-04-422683
Published: 2012
Includes: Supplemental data
Journal Articles

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

Clinical Trials & Observations
Peter Ouillette, Roxane Collins, Sajid Shakhan, Jinghui Li, Edward Peres, Lisa Kujawski, Moshe Talpaz, Mark Kaminski, Cheng Li, Kerby Shedden, Sami N. Malek
Journal: Blood
Blood (2011) 118 (11): 3051–3061.
https://doi.org/10.1182/blood-2010-12-327858
Published: 2011
Includes: Supplemental data
Journal Articles

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

Lisa Kujawski, Peter Ouillette, Harry Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, Sami N. Malek
Journal: Blood
Blood (2008) 112 (5): 1993–2003.
https://doi.org/10.1182/blood-2007-07-099432
Published: 2008
Includes: Supplemental data
Journal Articles

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Chris Saddler, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang, Sami N. Malek
Journal: Blood
Blood (2008) 111 (3): 1584–1593.
https://doi.org/10.1182/blood-2007-09-112698
Published: 2008
Includes: Supplemental data
Journal Articles

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Lisa Kujawski, MD, Sanjeev Shangary, PhD, Moshe Talpaz, MD, Mark Kaminski, MD, Harry Erba, Kerby Shedden, PhD, Shaomeng Wang, PhD, Chris Saddler, BS
Journal: Blood
Blood (2007) 110 (11): 224.
https://doi.org/10.1182/blood.V110.11.224.224
Published: 2007
Journal Articles

Genomic Complexity Identifies Patients with Agressive Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Harry Erba, MD, PhD, Chris Saddler, BS, Andrzej Jakubowiak, MD, Mark Kaminski, MD, Kerby Shedden, PhD, Lisa Kujawski, MD
Journal: Blood
Blood (2007) 110 (11): 489.
https://doi.org/10.1182/blood.V110.11.489.489
Published: 2007
Journal Articles

Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).

Andrzej Jakubowiak, Malathi Hari, Ammar Al-Zoubi, Tara Kendall, Yasser Khaled, Shin Mineishi, Mark Kaminski
Journal: Blood
Blood (2007) 110 (11): 4796.
https://doi.org/10.1182/blood.V110.11.4796.4796
Published: 2007
Journal Articles

Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) Shows Efficacy in Elderly Patients (pts) with Relapsed/Refractory Low-Grade (LG), Follicular, and Transformed Non-Hodgkin’s Lymphoma (NHL).

Stephanie A. Gregory, Andrew Zelenetz, Susan J. Knox, Julie Vose, John P. Leonard, Mark Kaminski
Journal: Blood
Blood (2004) 104 (11): 2630.
https://doi.org/10.1182/blood.V104.11.2630.2630
Published: 2004